NEW YORK (Reuters) – As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. FILE PHOTO: FDA Commissioner Scott Gottlieb speaks during an interview with Reuters in New York City, U.S., November 26, 2018. REUTERS/Brendan McDermid/File Photo Since leaving the FDA in April, Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates, one of the country’s largest venture capital firms where he worked prior to his time in government. But in an interview, Gottlieb said he intends to use his expertise to back therapeutic areas that other healthcare investors have overlooked due to concerns over how the treatments are paid for. Near the top of his list are companies researching new kinds of antibiotics, an issue he advocated for while at the FDA. “I’m very interested in finding opportunities in the anti-infective space, particularly around multi-drug resistant organisms,” Gottlieb said in an interview. “Anti-infectives have been unloved for a very long time. There’s a huge clinical need.” In many ways, it’s a contrarian bet. Global health officials have repeatedly warned… Read full this story
- Ex-Tudor manager's investment firm scores big in market turmoil
- AP FACT CHECK: Trump claims rising suicides if US stays shut
- Bars, restaurants and stores are boarded up as three million Americans prepare to file for unemployment and Donald Trump warns of a nationwide two-week quarantine to slow the spread of coronavirus
- Rosemary Gibson: We Need to Protect Medicine as ‘Strategic National Asset’ Against China’s Monopoly
- America could overtake Italy and become the new coronavirus epicenter after 'very large acceleration' in infections and 100 deaths in a day, warns WHO, as Trump ignores threat and vows to 'reopen' US
- Trump administration pushing fiscal stimulus in response to coronavirus crisis
- Text of Gov. John Hickenlooper’s speech
- 'Get a grip and test': Oxford University lecturer who was DENIED a coronavirus swab after being rushed to hospital with breathing difficulties slams Boris Johnson for failing to provide more tests
- Trump made 33 false claims about the coronavirus crisis in the first two weeks of March
- Brexit: What's in store for Indian markets?
- Is Anybody Home at Ben Carson’s HUD?
- Mirror Labour leadership live: Hopefuls grilled over how they'll win back towns like Dudley
Ex-FDA chief Gottlieb sees investment opportunity in 'unloved' antibiotics have 390 words, post on feeds.reuters.com at October 29, 2019. This is cached page on CHUTEU. If you want remove this page, please contact us.